Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is positioned for sustained outperformance because its Affera/Sphere-9 pulsed-field ablation platform is driving rapid Cardiac Ablation Solutions growth, with 88% worldwide growth in F1Q27 and management expecting the business to grow 2.5x the broader EP market in FY27. The bullish case is also supported by a broadened growth portfolio that includes Hugo robotics, Symplicity Spyral, and Altaviva, all of which expand addressable markets while helping offset softer areas and reinforcing mid-single-digit top-line growth and margin leverage. Financially, FY27 guidance implies about 7.25% to 7.75% organic revenue growth, adjusted EPS of $5.94 to $6.00, and gross-margin upside from a richer product mix, tariff refunds, and the eventual Diabetes separation.

Bears say

Medtronic is facing a cautious fundamental setup because FY27 guidance implies only 110 bps of organic revenue deceleration, from 6.5% in F1H27 to 5.4% in F2H27, while F2Q27 EPS is guided to $1.32-$1.34, down 2.2% Y/Y. The outlook is further pressured by about $200M of net tariff expense, a 50 bps drag to the FY27 gross margin estimate of 65.0% and a $0.13 headwind to adjusted EPS of $5.97, with future refunds not included in guidance. Beyond tariffs, the bear case centers on slower product growth, competitive encroachment, regulatory and reimbursement risk, and continuing weakness in Structural Heart and Neuromodulation that could keep margins under pressure.

Medtronic (MDT) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 21 analysts, Medtronic (MDT) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.